119th Congress · introduced in the House · Jan 3, 2025
Byron Nash Renal Medullary Carcinoma Awareness Act of 2023
Official title from Congress.gov
Latest action (Jan 3, 2025): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Jan 3, 2025)
Byron Nash Renal Medullary Carcinoma Awareness Act of 2023 [sic]
This bill allows states to receive federal payment under Medicaid for 50% of their costs for providing education on the risk of renal medullary carcinoma to individuals with sickle cell disease. (Renal medullary carcinoma is a rare kidney disease usually found in individuals with the sickle cell trait.)
No cosponsors.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Cancer · Digestive and metabolic diseases · Health promotion and preventive care · Medicaid
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
No matching lobbying reports found within coverage